UK considers reducing quarantine period for COVID-19 contacts

(Reuters) – Britain’s government is looking at how long those exposed to COVID-19 need to quarantine, Northern Ireland minister Brandon Lewis told Sky News on Sunday, commenting on reports that the self-isolation period could be reduced from 14 days.

Like many other European countries, the UK is facing a surge in infections. It has so far reported 884,457 coronavirus cases with 44,795 deaths, according to a Reuters tally.

The government has ordered those in England identified as being exposed to the virus to stay at home for 14 days, or face fines of up to 10,000 pounds ($13,043).

“Teams are looking at what we can do around those isolation periods, this will be scientifically led,” Lewis said when asked about reports the period could be reduced to 10 or seven days.

“We’re not ready to make a final decision or announcement on that yet, but we want to make sure we’re moving with the science, and indeed again, allowing people to live and work within this virus as best as we can.”

Lewis denied a report in the Sunday Times that some city workers and company bosses could be exempt from the quarantine period. He said any changes to the rules would apply to everybody.

($1 = 0.7667 pounds)

(Reporting by Maria Ponnezhath in Bengaluru and William James in London; Editing by Frances Kerry and Catherine Evans)

Source Article

Read more

Traditional Chinese Medicine Market Expected to Witness A CAGR Of More than 5% Over the Forecast Period 2020-2030 – Persistence Market Research

NEW YORK, Oct. 23, 2020 /PRNewswire/ — Traditional Chinese medicine is one of the oldest systems of health and wellness that has been used in China for thousands of years. Other medicines mainly focus on treating a disease. But traditional Chinese medicines aim to increase immune power and look at the entire well-being. The most common type of traditional Chinese medicines includes herbal products, acupuncture, and Tai Chi, among others.

According to a latest report published by PMR, the global traditional Chinese medicine marketis expected to witness a CAGR of more than 5% over the forecast period (2020–2030).

Key Takeaways from Traditional Chinese Medicine Market Study  

  • Non-traditional Chinese medicines is the leading segment by product in the global traditional Chinese medicine market. The Autism Spectrum disorder (ASD) segment has been gaining more traction in recent years, and is expected to expand at a rate of 6.7% during the forecast period.
  • North America is the leading region in the traditional Chinese medicine market, followed by Europe.
  • East and South Asia, including China, South Korea, Japan, India, and ASEAN countries, is the fastest-growing region in the traditional Chinese medicine market, due improving medical infrastructure.
  • Tong Ren Tang, Pfizer, and Novartis AG are amongst the leading players in the global traditional Chinese medicine market. These companies invest most of their revenue in R&D, and focus on strengthening their distribution channels to maintain a leading position in the traditional Chinese medicine market space.
  • 100+ health systems are partnering with retail chains, providing physician oversights and increased patient traffic to retail clinics, and extending health system networks to new patient populations.
  • The COVID-19 pandemic is a cause for concern, which has deprioritized non-essential medical treatments. This will hurt the growth of the global traditional Chinese medicine market in the short term

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/16219

“Increasing incidence of ADHD to boost growth of global traditional Chinese medicine market,” says a PMR analyst.

Rising prevalence of ADHD is a major factor contributing to revenue growth of the traditional Chinese medicine market across the globe. The exact cause of ADHD is still unclear, although genetic influence is observed in most cases.

As per data released by the Centers for Disease Control and Prevention (CDC), approximately 6.1 million (9.4%) – 388,000 children aged 2–5 years, 4 million children aged 6–11 years, and 3 million children aged 12–17 years – were diagnosed with ADHD in the U.S. In Spain, pooled prevalence of ADHD in a population of 361,580 representing children and adolescents was estimated at 6.8% from the last decade.

Get Customization on this Report: https://www.persistencemarketresearch.com/request-customization/16219 

Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of ADHD therapeutics such traditional Chinese medicines, as there is no specific treatment for this disorder

Product Innovation – Key Strategy of Traditional Chinese Medicine Market Players

Major players in the global traditional Chinese medicine market are introducing innovative products

Read more

Traditional Chinese Medicine Market Expected to Witness A CAGR Of More than 5% Over the Forecast Period 2020-2030

NEW YORK, Oct. 23, 2020 /PRNewswire/ — Traditional Chinese medicine is one of the oldest systems of health and wellness that has been used in China for thousands of years. Other medicines mainly focus on treating a disease. But traditional Chinese medicines aim to increase immune power and look at the entire well-being. The most common type of traditional Chinese medicines includes herbal products, acupuncture, and Tai Chi, among others.

Persistence_Market_Research

According to a latest report published by PMR, the global traditional Chinese medicine market
is expected to witness a CAGR of more than 5% over the forecast period (2020-2030).

Key Takeaways from Traditional Chinese Medicine Market Study

  • Non-traditional Chinese medicines is the leading segment by product in the global traditional Chinese medicine market. The Autism Spectrum disorder (ASD) segment has been gaining more traction in recent years, and is expected to expand at a rate of 6.7% during the forecast period.
  • North America is the leading region in the traditional Chinese medicine market, followed by Europe.
  • East and South Asia, including China, South Korea, Japan, India, and ASEAN countries, is the fastest-growing region in the traditional Chinese medicine market, due improving medical infrastructure.
  • Tong Ren Tang, Pfizer, and Novartis AG are amongst the leading players in the global traditional Chinese medicine market. These companies invest most of their revenue in R&D, and focus on strengthening their distribution channels to maintain a leading position in the traditional Chinese medicine market space.
  • 100+ health systems are partnering with retail chains, providing physician oversights and increased patient traffic to retail clinics, and extending health system networks to new patient populations.
  • The COVID-19 pandemic is a cause for concern, which has deprioritized non-essential medical treatments. This will hurt the growth of the global traditional Chinese medicine market in the short term

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/16219

“Increasing incidence of ADHD to boost growth of global traditional Chinese medicine market,” says a PMR analyst.

Rising prevalence of ADHD is a major factor contributing to revenue growth of the traditional Chinese medicine market across the globe. The exact cause of ADHD is still unclear, although genetic influence is observed in most cases.

As per data released by the Centers for Disease Control and Prevention (CDC), approximately 6.1 million (9.4%) – 388,000 children aged 2-5 years, 4 million children aged 6-11 years, and 3 million children aged 12-17 years – were diagnosed with ADHD in the U.S. In Spain, pooled prevalence of ADHD in a population of 361,580 representing children and adolescents was estimated at 6.8% from the last decade.

Get Customization on this Report: https://www.persistencemarketresearch.com/request-customization/16219

Prevalence of ADHD is rising at an alarming rate, which is expected to fuel revenue growth of ADHD therapeutics such traditional Chinese medicines, as there is no specific treatment for this disorder

Product Innovation – Key Strategy of Traditional Chinese Medicine Market Players

Major players in the global traditional Chinese medicine market are introducing innovative products to retain

Read more

COVID-19 Related Breast Cancer Surgery Delays Could Result in Nearly 3,000 Additional Deaths Over a 10 Year Period

Delays in treatment also place patients at higher risk of metastasis, increasing cost of care by more than $375 million during that time

Delays in breast cancer surgery due to the COVID-19 pandemic could lead to an additional 2,797 deaths over the next decade according to Kantar Health, a leading global healthcare data, analytics and research provider, Delays in treatments could result in an additional $376 million in treatment costs over that time period due to more patients developing metastasis. The analysis, released as part of World Breast Cancer Awareness Month, is based on Kantar Health’s CancerMPact® Patient Metrics database, a decision support resource for oncology market analysis, strategic planning and identifying commercial opportunities.

Research from the American Association of Cancer Research found that 32% of those who were diagnosed with breast cancer reported a delay in care. Of these patients, 22% reported a delay in screening and 9.3% reported a delay in treatment.

Kantar Health’s CancerMPact Patient Metrics database1 estimates the incidence of breast cancer in the United States in 2020 to be 335,779. Of those, 319,700 patients will be diagnosed with non-metastatic disease. If these patients with non-metastatic disease receive appropriate and timely care, they have good potential for a positive outcome. However, delays in care, especially surgery, compromises this. For breast cancer, a delay in surgery of 60 days is estimated to cause an increase in the number of deaths of 4% and 7% at five and ten years post-diagnosis respectively2.

Based on Kantar Health’s estimates of the total annual number of new cancer patients, it is expected that the number of patients diagnosed with non-metastatic during the first three months of the pandemic totaled 79,925 patients.

Of these patients, Kantar Health forecasts that deaths among breast cancer patients could increase by 1,598 deaths five years post-diagnosis and 2,797 deaths ten years post-diagnosis.

Further, Kantar Health expects an excess in the overall costs of cancer treatment due to COVID-19, as a proportion of patients will develop metastasis over the course of their disease. In the five years post-COVID-19, additional costs will total $215.2 million for breast cancer patients. In ten years, this number could almost double, to $376.7 million for breast cancer care.

“The effects of the pandemic will be felt deeply in many disease areas, but none more so than in oncology,” said Jeremy Brody, Chief Strategy Officer, Kantar Health. “It is important that patients continue to maintain their regular appointments and screenings to detect and treat breast cancer. The COVID-19 global pandemic needs to be a catalyst for the healthcare system to seek new ways to reach patients and ensure early detection screenings continue.”

Refs

  1. CancerMPact Patient Metrics Database [Internet]. Kantar Health. 2020 [cited May, 2020]. Available from: www.cancermpact.com.

  2. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, et al. Time to Surgery and Breast Cancer Survival in the United States. JAMA oncology. 2016;2(3):330-9.

About Kantar Health

Kantar Health, a division of Kantar, provides data, analytics and

Read more